# Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients

> **NCT00506688** · PHASE2 · COMPLETED · sponsor: **Mukoviszidose Institut gGmbH** · enrollment: 153 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** reduced glutathione sodium salt
- **DRUG:** 0.9% normal saline (control)

## Key facts

- **NCT ID:** NCT00506688
- **Lead sponsor:** Mukoviszidose Institut gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2012-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00506688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00506688, "Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00506688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*